Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Share-based Compensation: 2013-2025

Historic Share-based Compensation for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $3.2 million.

  • Fortress Biotech's Share-based Compensation fell 51.36% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 110.95%. This contributed to the annual value of $32.6 million for FY2024, which is 91.55% up from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Share-based Compensation is $3.2 million, which was down 80.96% from $16.8 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Share-based Compensation high stood at $16.8 million for Q2 2025, and its period low was $3.2 million during Q3 2025.
  • Over the past 3 years, Fortress Biotech's median Share-based Compensation value was $4.9 million (recorded in 2024), while the average stood at $6.9 million.
  • As far as peak fluctuations go, Fortress Biotech's Share-based Compensation skyrocketed by 337.10% in 2024, and later tumbled by 51.36% in 2025.
  • Quarterly analysis of 5 years shows Fortress Biotech's Share-based Compensation stood at $7.0 million in 2021, then dropped by 21.76% to $5.5 million in 2022, then plummeted by 32.73% to $3.7 million in 2023, then spiked by 337.10% to $16.2 million in 2024, then slumped by 51.36% to $3.2 million in 2025.
  • Its Share-based Compensation stands at $3.2 million for Q3 2025, versus $16.8 million for Q2 2025 and $6.3 million for Q1 2025.